Sex Differences in Outcomes of Intravenous Thrombolysis in Acute Ischemic Stroke Patients with Preadmission Use of Antiplatelets

[1]  Ana Catarina Fonseca,et al.  European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke , 2021, European stroke journal.

[2]  J. Wellmann,et al.  Female Stroke: Sex Differences in Acute Treatment and Early Outcomes of Acute Ischemic Stroke. , 2021, Stroke.

[3]  M. Woodward,et al.  Author response: Sex differences in treatment and outcome after stroke: Pooled analysis including 19,000 participants , 2020, Neurology.

[4]  C. Gerloff,et al.  Safety and efficacy of intravenous thrombolysis in stroke patients on prior antiplatelet therapy in the WAKE-UP trial , 2020, Neurological Research and Practice.

[5]  Zhenquan Liu,et al.  Sex Differences of Acute Stroke Treatment and in Hospital Outcomes After Intravenous Thrombolysis in Patients With Ischemic Stroke , 2020, Frontiers in Neurology.

[6]  D. DeMeo,et al.  Sex and gender: modifiers of health, disease, and medicine , 2020, The Lancet.

[7]  C. Nolte,et al.  Prior Dual Antiplatelet Therapy and Thrombolysis in Acute Stroke , 2020, Annals of neurology.

[8]  Haiying Li,et al.  Sex Dimorphisms in Ischemic Stroke: From Experimental Studies to Clinic , 2020, Frontiers in Neurology.

[9]  J. Manson,et al.  Clinical Advances in Sex- and Gender-Informed Medicine to Improve the Health of All: A Review. , 2020, JAMA internal medicine.

[10]  M. Woodward,et al.  Sex differences in treatment and outcome after stroke , 2019, Neurology.

[11]  R. de Caterina,et al.  Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. , 2019, International journal of cardiology.

[12]  Maheshwari Patel,et al.  Study , 2019, Definitions.

[13]  D. Strbian,et al.  Intravenous Thrombolysis for Ischemic Stroke Patients on Dual Antiplatelets , 2018, Annals of Neurology.

[14]  S. Gall,et al.  Sex differences in the evaluation and treatment of acute ischaemic stroke , 2018, The Lancet Neurology.

[15]  W. Ambrosius,et al.  Factors Mediating Outcome After Stroke: Gender, Thrombolysis, and Their Interaction , 2018, Translational Stroke Research.

[16]  P. Schellinger,et al.  Another Enchantment From ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study): Are Savings and Safety More Salutary Than Efficacy? , 2017, Stroke.

[17]  A. Alexandrov,et al.  Antiplatelet pretreatment and outcomes in intravenous thrombolysis for stroke: a systematic review and meta-analysis , 2017, Journal of Neurology.

[18]  Jonathan Sturm,et al.  Sex Differences in Long-Term Mortality After Stroke in INSTRUCT (INternational STRoke oUtComes sTudy): A Meta-Analysis of Individual Participant Data , 2017, Circulation. Cardiovascular quality and outcomes.

[19]  J. Grotta,et al.  Sex and Stroke in Thrombolyzed Patients and Controls , 2017, Stroke.

[20]  S. Lageman,et al.  National Institute of Neurological Disorders and Stroke , 2017 .

[21]  C. Nolte,et al.  Sex Differences and Functional Outcome After Intravenous Thrombolysis , 2017, Stroke.

[22]  M. Woodward,et al.  Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study) , 2017, Stroke.

[23]  J. Tao,et al.  Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy: A Systematic Review and Meta‐analysis of 19 Studies , 2016, Journal of the American Heart Association.

[24]  P. Michel,et al.  Ein Werkzeug für die Qualitätssicherung und Forschung , 2016 .

[25]  I. Surakka,et al.  Post‐thrombolytic blood pressure and symptomatic intracerebral hemorrhage , 2015, European journal of neurology.

[26]  Eric E. Smith,et al.  Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator. , 2016, JAMA neurology.

[27]  D. Zheng,et al.  Prior Antiplatelet Agent Use and Outcomes after Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials , 2015, International journal of stroke : official journal of the International Stroke Society.

[28]  P. Sandercock,et al.  Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .

[29]  R. de Caterina,et al.  Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper. , 2014, European heart journal.

[30]  F. Franconi,et al.  Sex and gender influences on pharmacological response: an overview , 2014, Expert review of clinical pharmacology.

[31]  T. Tatlisumak,et al.  Does Sex Influence the Response to Intravenous Thrombolysis in Ischemic Stroke?: Answers From Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register , 2013, Stroke.

[32]  J. Saver,et al.  Statistical Analysis of the Primary Outcome in Acute Stroke Trials , 2012, Stroke.

[33]  M. Sabatine,et al.  Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. , 2012, Journal of the American College of Cardiology.

[34]  D. Angiolillo,et al.  Impact of race and gender on antithrombotic therapy , 2010, Thrombosis and Haemostasis.

[35]  L. Soinne,et al.  Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy at Stroke Onset , 2010, Stroke.

[36]  Scott E Kasner,et al.  Factors Associated With Intracerebral Hemorrhage After Thrombolytic Therapy for Ischemic Stroke: Pooled Analysis of Placebo Data From the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials , 2009, Stroke.

[37]  J. De Keyser,et al.  Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. , 2008, Archives of neurology.

[38]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[39]  W. Koroshetz,et al.  Sex as a predictor of outcomes in patients treated with thrombolysis for acute stroke , 2007, Neurology.

[40]  Scott E Kasner,et al.  Clinical interpretation and use of stroke scales , 2006, The Lancet Neurology.

[41]  J. Segal,et al.  Platelet counts differ by sex, ethnicity, and age in the United States. , 2006, Annals of epidemiology.

[42]  Gianni Tognoni,et al.  Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials , 2006, JAMA.

[43]  R. Califf,et al.  Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials , 2002, The Lancet.

[44]  P. Bray,et al.  Gender Differences in Platelet GPIIb-IIIa Activation , 1997, Thrombosis and Haemostasis.

[45]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[46]  James N. Davis,et al.  Interrater reliability of the NIH stroke scale. , 1989, Archives of neurology.

[47]  P. Ramwell,et al.  Sex and age differences in human platelet aggregation , 1975, Nature.